StockData
Biogen Inc. logo

Biogen Inc. (BIIB) shareholders

BIIBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 28, 2026Score 4/3056% above fair value
$250.79−0.86 (-0.34%)

Close on Nov 17, 2026Market cap $37.07BP/E 107.2Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
96.2%
142M of 148M shares
Institutional holders
1,041
126 new, 83 sold out
Net institutional buying
7M
In Q2 2026
Insider trades, 12 months
1 buys · 4 sales
Net sold $904.83K

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Abigail P. Johnson
Joint filing with FMR LLC (12.40%)
18,294,52412.40%13G (passive) amendmentJun 30, 2026
Primecap Management Co/Ca/14,954,69710.20%13G (passive) amendmentSep 30, 2025
BlackRock, Inc.12,506,6818.50%13G (passive) amendmentMar 31, 2025
Vanguard Capital Management10,989,5627.48%13G (passive)Mar 31, 2026
State Street Corporation7,570,5895.10%13G (passive)Sep 30, 2026

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of BIIBValueChange% of portfolio
FMR LLC18,217,23912.32%$3.94B+5,409,6980.17%
BlackRock, Inc.15,985,73610.81%$3.45B+11,1350.05%
Primecap Management Co/Ca/15,154,60610.25%$3.27B+396,9991.94%
Vanguard Capital Management LLC9,651,1176.53%$2.09B+113,7000.04%
State Street Corp7,344,3274.97%$1.59B+176,4050.05%
Vanguard Portfolio Management LLC6,604,9364.47%$1.43B+73,2090.06%
Geode Capital Management, LLC4,449,2953.01%$957.94M+106,6930.05%
Wellington Management Group Llp3,117,4692.11%$673.56M+155,8280.12%
Norges Bank2,580,0331.75%$557.44MNew0.06%
Morgan Stanley2,411,2711.63%$520.98M+240,3310.03%
Aqr Capital Management LLC1,936,8591.31%$416.93M+13,3020.15%
JPMorgan Chase & Co1,823,1401.23%$394.95M−192,8690.02%
Invesco Ltd.1,803,9441.22%$389.76M+58,6890.03%
Amundi1,516,8311.03%$327.73M+726,0040.08%
Legal & General Group Plc1,493,2891.01%$322.64M+143,4570.07%
Northern Trust Corp1,429,4900.97%$308.86M−17,0890.04%
Boston Partners1,263,4290.85%$272.85M−436,6490.24%
UBS Asset Management Americas Inc1,255,1680.85%$271.19M−122,4000.05%
Goldman Sachs Group Inc1,230,3900.83%$265.84M+179,2960.02%
Dimensional Fund Advisors LP1,148,5680.78%$248.17M+69,4490.04%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 20261,041142M96.2%126 / 426293 / 8316M9M
Q1 20261,012135M91.3%137 / 401291 / 10728M16M
Q4 20251,001141M95.4%190 / 322299 / 8122M13M
Q3 2025908133M89.7%124 / 323269 / 7413M11M
Q2 2025867131M88.4%96 / 342264 / 10013M12M
Q1 2025882130M87.9%125 / 331274 / 10610M13M
Q4 2024876133M89.6%132 / 299323 / 15917M19M
Q3 2024918135M91.5%101 / 271378 / 11826M10M
Q2 2024944134M90.5%101 / 323336 / 978M12M
Q1 2024953138M93.3%105 / 302355 / 14612M10M
Q4 20231,003136M92.0%136 / 286376 / 8118M7M
Q3 2023965125M84.8%91 / 333346 / 1198M8M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

771 funds held BIIB in Q2 2026, 39% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of BIIBValue% of fundAs of
Vanguard Primecap Fund8,359,8805.66%$1.81B1.88%Jun 30, 2026
Fidelity Contrafund4,988,6553.37%$1.08B0.60%Jun 30, 2026
Vanguard Total Stock Market Index Fund4,687,9853.17%$1.01B0.04%Jun 30, 2026
Vanguard 500 Index Fund3,827,8622.59%$827.05M0.05%Jun 30, 2026
Vanguard Mid-Cap Index Fund3,199,0782.16%$691.19M0.31%Jun 30, 2026
Vanguard Health Care Fund2,745,4861.86%$557.20M1.46%Jul 31, 2026
Vanguard Capital Opportunity Fund2,624,3171.78%$567.01M1.73%Jun 30, 2026
iShares Core S&P 500 ETF2,031,0411.37%$438.83M0.05%Jun 30, 2026
Strategic Advisers Fidelity U.S. Total Stock Fund2,027,4061.37%$397.37M0.16%May 31, 2026
Fidelity 500 Index Fund1,878,0801.27%$368.10M0.04%May 31, 2026
Vanguard Value Index Fund1,403,9500.95%$303.34M0.12%Jun 30, 2026
Vanguard Primecap Core Fund1,316,9360.89%$284.54M1.57%Jun 30, 2026
Fidelity Contrafund K61,075,7230.73%$232.42M0.62%Jun 30, 2026
State Street(R) Health Care Select Sector SPDR(R) ETF1,042,9980.71%$225.35M0.56%Jun 30, 2026
iShares Biotechnology ETF1,037,1640.70%$224.09M2.47%Jun 30, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Christopher ViehbacherPresident and CEO, Director21,0950.01%Feb 17, 2026
Jane GroganHead of Research4,4080.00%Nov 2, 2026
Sean GodboutChief Accounting Officer1,4590.00%Oct 5, 2026
Michael PariniChief Legal Officer––Sep 3, 2026
Adam KeeneyHead of Corporate Development6,3650.00%May 5, 2026
Robin KramerChief Financial Officer9,0240.01%Feb 17, 2026
Susan H. AlexanderEVP Chief Legal Officer58,5370.04%Feb 17, 2026
Ginger GregoryEVP, Human Resources22,3590.02%Feb 17, 2026
Priya SinghalHead of Development8,0430.01%Feb 17, 2026
Rachid IzzarHead of Global Product Strat.11,7860.01%Feb 17, 2026
Nicole MurphyHead of Pharm Ops and Tech19,6110.01%Feb 17, 2026
Michael R. McDonnellEVP, Chief Financial Officer24,3410.02%Feb 12, 2025
Lloyd MinorDirector2,6890.00%Aug 5, 2026
Maria C. FreireDirector8,8200.01%Jun 11, 2026
Jesus B. MantasDirector11,2630.01%Jun 11, 2026
Menelas N. PangalosDirector3,8750.00%Jun 11, 2026
Stephen A. SherwinDirector15,1930.01%Jun 11, 2026
William A. HawkinsDirector10,3650.01%Jun 11, 2026
Susan LangerDirector6,6340.00%Jun 11, 2026
Monish D. PatolawalaDirector5,2150.00%Jun 11, 2026
Eric K. RowinskyDirector25,8440.02%Jun 11, 2026
Caroline DorsaDirector31,0020.02%Jun 18, 2025

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Jane Grogan
Head of Research
Oct 30, 2026Tax withholding−345$253.62$87.50K4,408
Jane Grogan
Head of Research
Oct 30, 2026Option exercise+695––4,753
Sean Godbout
Chief Accounting Officer
Oct 2, 2026Tax withholding−8$219.88$1.76K1,459
Sean Godbout
Chief Accounting Officer
Oct 2, 2026Option exercise+27––1,467
Lloyd Minor
Director
Aug 4, 2026Sale(10b5-1 plan)−593$200.96$119.17K2,689
Lloyd Minor
Director
Aug 3, 2026Sale(10b5-1 plan)−593$203.34$120.58K3,282
Maria C. Freire
Director
Jun 9, 2026Award+2,005––8,820
Stephen A. Sherwin
Director
Jun 9, 2026Award+1,505––15,193
Monish D. Patolawala
Director
Jun 9, 2026Award+1,505––5,215
Jesus B. Mantas
Director
Jun 9, 2026Award+1,505––11,263
Susan Langer
Director
Jun 9, 2026Award+1,505––6,634
Lloyd Minor
Director
Jun 9, 2026Award+1,505––3,875
Eric K. Rowinsky
Director
Jun 9, 2026Award+1,505––25,844
Menelas N. Pangalos
Director
Jun 9, 2026Award+1,505––3,875
Menelas N. Pangalos
Director
Jun 9, 2026Option exercise+2,370––2,370
William A. Hawkins
Director
Jun 9, 2026Award+1,505––10,365
Adam Keeney
Head of Corporate Development
May 1, 2026Tax withholding−455$187.06$85.11K6,365
Adam Keeney
Head of Corporate Development
May 1, 2026Option exercise+939––6,820
Sean Godbout
Chief Accounting Officer
Apr 1, 2026Option exercise+181––1,396
Sean Godbout
Chief Accounting Officer
Apr 1, 2026Tax withholding−54$183.78$9.92K1,342
Nicole Murphy
Head of Pharm Ops and Tech
Feb 12, 2026Buy+3$195.04$58519,611
Priya Singhal
Head of Development
Feb 9, 2026Sale(10b5-1 plan)−2,660$199.83$531.55K8,043
Christopher Viehbacher
President and CEO, Director
Feb 6, 2026Tax withholding−4,356$201.18$876.34K21,095
Christopher Viehbacher
President and CEO, Director
Feb 6, 2026Option exercise+15,453––36,548
Christopher Viehbacher
President and CEO, Director
Feb 6, 2026Tax withholding−6,624$201.18$1.33M29,924
Christopher Viehbacher
President and CEO, Director
Feb 6, 2026Option exercise+9,008––25,451
Nicole Murphy
Head of Pharm Ops and Tech
Feb 6, 2026Option exercise+4,683––21,016
Nicole Murphy
Head of Pharm Ops and Tech
Feb 6, 2026Option exercise+2,102––16,324
Nicole Murphy
Head of Pharm Ops and Tech
Feb 6, 2026Tax withholding−1,017$201.18$204.60K15,307
Nicole Murphy
Head of Pharm Ops and Tech
Feb 6, 2026Option exercise+1,940––17,247
Nicole Murphy
Head of Pharm Ops and Tech
Feb 6, 2026Tax withholding−914$201.18$183.88K16,333
Nicole Murphy
Head of Pharm Ops and Tech
Feb 6, 2026Tax withholding−1,408$201.18$283.26K19,608
Jane Grogan
Head of Research
Feb 6, 2026Option exercise+1,385––3,176
Jane Grogan
Head of Research
Feb 6, 2026Tax withholding−407$201.18$81.88K2,769
Jane Grogan
Head of Research
Feb 6, 2026Option exercise+1,873––4,642
Jane Grogan
Head of Research
Feb 6, 2026Tax withholding−584$201.18$117.49K4,058
Susan H. Alexander
EVP Chief Legal Officer
Feb 6, 2026Option exercise+2,190––38,455
Susan H. Alexander
EVP Chief Legal Officer
Feb 6, 2026Tax withholding−1,059$201.18$213.05K37,396
Susan H. Alexander
EVP Chief Legal Officer
Feb 6, 2026Option exercise+1,940––39,336
Susan H. Alexander
EVP Chief Legal Officer
Feb 6, 2026Tax withholding−931$201.18$187.30K38,405
Susan H. Alexander
EVP Chief Legal Officer
Feb 6, 2026Tax withholding−1,514$201.18$304.59K41,807
Susan H. Alexander
EVP Chief Legal Officer
Feb 6, 2026Option exercise+4,916––43,321
Adam Keeney
Head of Corporate Development
Feb 6, 2026Tax withholding−589$201.18$118.50K3,597
Adam Keeney
Head of Corporate Development
Feb 6, 2026Option exercise+1,802––4,186
Adam Keeney
Head of Corporate Development
Feb 6, 2026Option exercise+3,278––6,875
Adam Keeney
Head of Corporate Development
Feb 6, 2026Tax withholding−994$201.18$199.97K5,881
Robin Kramer
Chief Financial Officer
Feb 6, 2026Tax withholding−207$201.18$41.64K9,024
Robin Kramer
Chief Financial Officer
Feb 6, 2026Option exercise+789––8,801
Robin Kramer
Chief Financial Officer
Feb 6, 2026Tax withholding−273$201.18$54.92K8,528
Robin Kramer
Chief Financial Officer
Feb 6, 2026Tax withholding−1,063$201.18$213.85K11,472
Robin Kramer
Chief Financial Officer
Feb 6, 2026Option exercise+3,511––12,535
Robin Kramer
Chief Financial Officer
Feb 6, 2026Option exercise+703––9,231
Priya Singhal
Head of Development
Feb 6, 2026Tax withholding−1,056$201.18$212.45K7,432
Priya Singhal
Head of Development
Feb 6, 2026Option exercise+4,683––12,115
Priya Singhal
Head of Development
Feb 6, 2026Tax withholding−1,412$201.18$284.07K10,703
Priya Singhal
Head of Development
Feb 6, 2026Option exercise+2,217––8,488
Ginger Gregory
EVP, Human Resources
Feb 6, 2026Tax withholding−1,132$201.18$227.74K22,359
Ginger Gregory
EVP, Human Resources
Feb 6, 2026Tax withholding−666$201.18$133.99K19,745
Ginger Gregory
EVP, Human Resources
Feb 6, 2026Option exercise+1,802––20,411
Ginger Gregory
EVP, Human Resources
Feb 6, 2026Tax withholding−791$201.18$159.13K18,609

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
3.70%
5M shares short
Days to cover
4.0
At 1M shares a day
Change since last report
-0.9%
From 6M shares
Short volume, 20 days
61.1%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Biogen's stock actually held short. Settlement fails (shares not delivered on time) peaked at 49,163 shares on Sep 28, 2026 over the last 90 days.

Planned insider sales

Notices of proposed sale filed on Form 144 before shares are sold

SellerFiledSharesMarket valuePlanned saleAcquired through
Lloyd Minor
Director
Aug 4, 2026593$119.17KAug 4, 2026Restricted Stock Vesting
Lloyd Minor
Director
Aug 3, 2026593$120.58KAug 3, 2026Restricted Stock Vesting
Priya Singhal
Officer
Feb 9, 20262,660$531.55KFeb 9, 2026Restricted Stock Vesting
Priya Singhal
Officer
Feb 2, 2026748$134.12KFeb 2, 2026Restricted Stock Vesting
Priya Singhal
Officer
Sep 2, 2025517$69.05KSep 2, 2025Restricted Stock Vesting
Rachid Izzar
Officer
Jul 8, 20252,223$300.11KJul 8, 2025Restricted Stock Vesting
Priya Singhal
Officer
May 19, 20253,806$480.51KMay 19, 2025Restricted Stock Vesting
Stephen A. Sherwin
Director
Mar 7, 20258,760$1.29MMar 7, 2025Restricted Stock Units
Priya Singhal
Officer
Dec 9, 2024110$17.29KDec 9, 2024Restricted Stock Vesting
Priya Singhal
Officer
Sep 3, 2024431$88.02KSep 3, 2024Restricted Stock Vesting
Priya Singhal
Officer
Apr 2, 202493$19.82KApr 2, 2024ESPP Purchase
Priya Singhal
Officer
Feb 22, 2024262$57.96KFeb 22, 2024Performance Shares
Priya Singhal
Officer
Feb 21, 2024108$23.92KFeb 21, 2024Performance Shares
Priya Singhal
Officer
Feb 12, 2024419$100.33KFeb 12, 2024Restricted Stock Vesting
Priya Singhal
Officer
Feb 2, 2024634$155.92KFeb 2, 2024Restricted Stock Vesting

Congress trades

40 trades in Biogen reported by 15 members of the House

MemberTypeTradedAmountFiled
Maria Elvira Salazar
FL27
Sold (part)Sep 24, 2026$1K–15KOct 7, 2026
Kevin Hern
OK01
SoldAug 18, 2026$1K–15KSep 1, 2026
Gilbert Cisneros
CA31
BoughtJun 5, 2026$1K–15KJul 2, 2026
Maria Elvira Salazar
FL27
SoldJun 2, 2026$15K–50KJul 7, 2026
Maria Elvira Salazar
FL27
BoughtMay 12, 2026$1K–15KJun 8, 2026
Maria Elvira Salazar
FL27
BoughtMay 11, 2026$50K–100KJun 8, 2026
Maria Elvira Salazar
FL27
BoughtMay 11, 2026$1K–15KJun 8, 2026
Gilbert Cisneros
CA31
BoughtJan 30, 2026$1K–15KFeb 13, 2026
Rob Bresnahan
PA08
BoughtMay 15, 2025$1K–15KJun 9, 2025
Rob Bresnahan
PA08
SoldApr 8, 2025$1K–15KMay 8, 2025
Rob Bresnahan
PA08
BoughtFeb 25, 2025$1K–15KMar 27, 2025
Rohit Khanna
CA17 · child
SoldApr 26, 2024$1K–15KMay 6, 2024
Rohit Khanna
CA17 · child
BoughtDec 5, 2023$15K–50KJan 4, 2024
Daniel Goldman
NY10
Sold (part)Mar 6, 2023$1K–15KApr 17, 2023
Shri Thanedar
MI13
SoldJan 23, 2023$15K–50KFeb 9, 2023
Kathy Manning
NC06 · joint account
SoldAug 3, 2022$1K–15KSep 14, 2022
Kathy Manning
NC06 · joint account
BoughtJul 20, 2022$1K–15KAug 10, 2022
Josh Gottheimer
NJ05 · joint account
SoldMar 17, 2022$1K–15KApr 17, 2022
Kathy Manning
NC06 · spouse
SoldJan 14, 2022$1K–15KFeb 11, 2022
Josh Gottheimer
NJ05 · joint account
BoughtJan 10, 2022$1K–15KFeb 18, 2022
Josh Gottheimer
NJ05 · joint account
Sold (part)Dec 9, 2021$1K–15KJan 10, 2022
Josh Gottheimer
NJ05 · joint account
BoughtOct 18, 2021$1K–15KNov 15, 2021
Josh Gottheimer
NJ05 · joint account
Sold (part)Sep 15, 2021$1K–15KOct 13, 2021
Josh Gottheimer
NJ05 · joint account
BoughtJun 8, 2021$1K–15KJul 15, 2021
Peter Meijer
MI03
SoldFeb 16, 2021$15KMar 16, 2021
Byron Donalds
FL19
SoldFeb 2, 2021$1K–15KNov 8, 2024
1375 days late
Christopher L. Jacobs
NY27
SoldJan 4, 2021$1K–15KFeb 17, 2021
Gilbert Cisneros
CA31
SoldDec 22, 2020$1K–15KJan 11, 2021
Gilbert Cisneros
CA31
BoughtSep 16, 2020$1K–15KOct 14, 2020
Josh Gottheimer
NJ05 · joint account
BoughtJul 7, 2020$1K–15KAug 10, 2020
Gilbert Cisneros
CA31
BoughtApr 29, 2020$1K–15KMay 13, 2020
Gilbert Cisneros
CA31
SoldMar 18, 2020$1K–15KApr 16, 2020
Gilbert Cisneros
CA31
BoughtFeb 7, 2020$1K–15KMar 10, 2020
Dean Phillips
MN03
Sold (part)Sep 11, 2019$1K–15KOct 11, 2019
Dean Phillips
MN03
Sold (part)Aug 13, 2019$1K–15KSep 16, 2019
Donna Shalala
FL27
SoldJun 24, 2019$1K–15KApr 27, 2020
308 days late
Dean Phillips
MN03
BoughtJun 20, 2019$1K–15KJul 11, 2019
Dean Phillips
MN03
Sold (part)May 13, 2019$1K–15KJun 13, 2019
Gilbert Cisneros
CA31
SoldMay 9, 2019$1K–15KJun 18, 2019
Nicholas Van Taylor
TX03 · spouse
SoldMar 25, 2019$1K–15KApr 15, 2019

See a number that looks wrong?